Editas Medicine reported earnings per share of -76 cents. This was below the analyst estimate for EPS of -67 cents. The company reported revenue of $1.14 million. This was 85.63% worse than the ...

Reports FY24 revenue $2.983M vs $0 last year. “Entering 2025 marks the next chapter for Prime Medicine (PRME) as we look to share initial data for our most advanced product candidate ...

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on IRON: Disc Medicine NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Equities researchers at Chardan Capital issued their FY2025 earnings per share estimates for Prime Medicine in a report issued on Monday, March 10th. Chardan Capital analyst G. Livshits anticipates ...

Disc Medicine, Inc. (IRON) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- ...

Illumina exhibited stable performance in its latest earnings, meeting revenue estimates while navigating rising expenses and legal costs.

Valuation and Earnings This table compares Clearmind Medicine and its rivals revenue, earnings per share (EPS) and valuation. Gross Revenue Net Income Price/Earnings Ratio Clearmind Medicine N/A ...

Editas (EDIT) delivered earnings and revenue surprises of -41.03% and 19.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Adjusted EPS of $2.04 exceeded analyst estimates of $1.99. Revenue reached $22.5 billion, surpassing expectations by 0.4%. Sales in the Innovative Medicine and MedTech segments drove top-line growth.